Carregant...
Management of newly diagnosed immune thrombocytopenia: can we change outcomes?
Immune thrombocytopenia resulting from antibody-mediated platelet destruction combined with impaired platelet production is a common cause of thrombocytopenia. The decision to treat newly diagnosed patients is based on several factors including ceasing hemorrhagic manifestations, increasing the plat...
Guardat en:
| Publicat a: | Blood Adv |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5737126/ https://ncbi.nlm.nih.gov/pubmed/29296878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017009860 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|